Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism. Issue 6 (June 2015)
- Record Type:
- Journal Article
- Title:
- Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism. Issue 6 (June 2015)
- Main Title:
- Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism
- Authors:
- Vergaro, Giuseppe
Fatini, Cinzia
Sticchi, Elena
Vassalle, Cristina
Gensini, Gianfranco
Ripoli, Andrea
Rossignol, Patrick
Passino, Claudio
Emdin, Michele
Abbate, Rosanna - Abstract:
- Abstract : Aims: Refractory hyperaldosteronism is frequently observed in heart failure patients on up-to-date treatment, and holds prognostic value. Our aim was to identify which factors, either genetic or nongenetic, are associated with refractory hyperaldosteronism. Methods: We enrolled 109 consecutive patients with left ventricular systolic dysfunction [left ventricular ejection fraction (LVEF) 32 ± 10%; 86% males; age 65 ± 13 years (mean ± standard deviation)] on optimized adrenergic and renin-angiotensin-aldosterone system (RAAS) antagonism, undergoing clinical and neuroendocrine characterization, and genotyping for six polymorphisms in key RAAS-regulating genes [angiotensinogen (AGT M235T), angiotensin-converting enzyme (ACE-240A>T and I/D), angiotensin II type I receptor (AGTR1 1166A>C), aldosterone synthase (CYP11B2-344C>T) and renin (REN rs7539596)]. Results: Patients with refractory hyperaldosteronism ( n = 41, 38%, with plasma concentration >180 ng/l, URL, median 283 ng/l, interquartile range 218–433), when compared with those without (106 ng/l, 74–144; P < 0.001), were not different either for treatment or LVEF, while presented with different AGT M235T genotype distribution ( P = 0.047). After adjustment for several humoral, instrumental, functional and therapeutical variables, only plasma renin activity (PRA) ( P < 0.001) and potassium ( P = 0.027) were independently associated with refractory hyperaldosteronism. Among polymorphisms, only AGT M235T ( PAbstract : Aims: Refractory hyperaldosteronism is frequently observed in heart failure patients on up-to-date treatment, and holds prognostic value. Our aim was to identify which factors, either genetic or nongenetic, are associated with refractory hyperaldosteronism. Methods: We enrolled 109 consecutive patients with left ventricular systolic dysfunction [left ventricular ejection fraction (LVEF) 32 ± 10%; 86% males; age 65 ± 13 years (mean ± standard deviation)] on optimized adrenergic and renin-angiotensin-aldosterone system (RAAS) antagonism, undergoing clinical and neuroendocrine characterization, and genotyping for six polymorphisms in key RAAS-regulating genes [angiotensinogen (AGT M235T), angiotensin-converting enzyme (ACE-240A>T and I/D), angiotensin II type I receptor (AGTR1 1166A>C), aldosterone synthase (CYP11B2-344C>T) and renin (REN rs7539596)]. Results: Patients with refractory hyperaldosteronism ( n = 41, 38%, with plasma concentration >180 ng/l, URL, median 283 ng/l, interquartile range 218–433), when compared with those without (106 ng/l, 74–144; P < 0.001), were not different either for treatment or LVEF, while presented with different AGT M235T genotype distribution ( P = 0.047). After adjustment for several humoral, instrumental, functional and therapeutical variables, only plasma renin activity (PRA) ( P < 0.001) and potassium ( P = 0.027) were independently associated with refractory hyperaldosteronism. Among polymorphisms, only AGT M235T ( P = 0.038) was associated with refractory hyperaldosteronism, after adjustment for nongenetic variables. Conclusions: In conclusion, refractory hyperaldosteronism in heart failure may be influenced by AGT M235T polymorphism, among RAAS candidate genes, and by PRA, which may represent, respectively, a constitutive (genotype dependent) and a nongenetic (phenotype-dependent) trigger for aldosterone elevation. Abstract : Supplemental Digital Content is available in the text … (more)
- Is Part Of:
- Journal of cardiovascular medicine. Volume 16:Issue 6(2015:Jun.)
- Journal:
- Journal of cardiovascular medicine
- Issue:
- Volume 16:Issue 6(2015:Jun.)
- Issue Display:
- Volume 16, Issue 6 (2015)
- Year:
- 2015
- Volume:
- 16
- Issue:
- 6
- Issue Sort Value:
- 2015-0016-0006-0000
- Page Start:
- Page End:
- Publication Date:
- 2015-06
- Subjects:
- aldosterone -- genetic polymorphism -- heart failure -- renin -- renin angiotensin system
Cardiology -- Periodicals
Cardiovascular system -- Diseases -- Periodicals
Cardiology -- Periodicals
Cardiovascular Diseases -- Periodicals
616.1005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&PAGE=toc&D=ovft&AN=01244665-000000000-00000 ↗
http://www.jcardiovascularmedicine.com/pt/re/jcm/home.htm ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.2459/JCM.0000000000000156 ↗
- Languages:
- English
- ISSNs:
- 1558-2027
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4954.867300
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 5208.xml